Drug Trial Radar · NCT03522415
Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: May 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
275
Actual
Start
May 28, 2018
Primary completion
Apr 5, 2020
Study completion Sep 11, 2020
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- May 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To compare the efficacy between the HLX01 group and the placebo group through the proportion of subjects meeting the ACR20 improvement criteria for remission
Conditions
- Moderately to Severely Active Rheumatoid Arthritis
Interventions
HLX01Drug
HLX01,Recombinant Human-mouse Chimeric Anti-CD20 Monoclonal Antibody Injection is recombinant human-mouse chimeric anti-cd20 CD20 monoclonal antibody.
Methotrexate(MTX)Drug
Methotrexate is a slow-acting antirheumatic drug.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ACR20Time frame: 24 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jiujiang No.1 peoples's hospital
Jiujiang, Jiangxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.